For research use only. Not for therapeutic Use.
MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i)[1].
| Catalog Number | I045223 |
| CAS Number | 899759-16-1 |
| Synonyms | N-[3-[6-(4-methylpiperazin-1-yl)pyridazin-3-yl]phenyl]naphthalene-2-carboxamide |
| Molecular Formula | C26H25N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C26H25N5O/c1-30-13-15-31(16-14-30)25-12-11-24(28-29-25)21-7-4-8-23(18-21)27-26(32)22-10-9-19-5-2-3-6-20(19)17-22/h2-12,17-18H,13-16H2,1H3,(H,27,32) |
| InChIKey | CVHOXUUPSXOTPM-UHFFFAOYSA-N |
| SMILES | CN1CCN(CC1)C2=NN=C(C=C2)C3=CC(=CC=C3)NC(=O)C4=CC5=CC=CC=C5C=C4 |
| Reference | [1]. Sáez AJG, et, al. Modulation of mixed lineage kinase domain-like protein signaling. WO2021224505A1. |
